Statistical analysis (Table S3) performed on the data obtained throughout the study (up to day 41) showed a substantial and significant decrease in tumor volume at day 41 in mice in group 2 treated with the lowest dose of CC48 (GP2, 10 mg/kg), compared to the control group (vehicle). The gene discussed is GP2; the disease is neoplasm.